DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT06263595

Completed

Semaglutide and Preoperative Residual Gastric Volumes

Mitigating Harm: Assessing Preoperative Residual Gastric Volumes to Risk Stratify Patients Administering Semaglutide

Assets

GLP-1 / incretin class catch-all / Semaglutide

Listed sites

1

Recruiting sites

—

Enrollment

94

actual

Study population

Perioperative / gastric aspiration risk

Key I/E criterion

—

Primary endpoint

•Number of participants presenting with a full stomach

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06263595
Org study IDREB23-1754

Timeline

Milestones

Study first posted2024-02-16actual
Study start2024-05-31actual
Primary completion2025-05-16actual
Study completion2025-05-16actual
Last update posted2026-04-28actual

Assets

Investigational agents

GLP-1 / incretin class catch-allSemaglutide

Study populations

Who this study enrolls

Perioperative / gastric aspiration risk

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted
Sampling methodNon probability sample

Study population text

Elective surgical patients meeting inclusion/exclusion criteria at the South Health Campus (Calgary, AB, Canada)

Inclusion criteria

•all elective surgical patients (> 18 years of age)
•followed institutional fasting protocol for surgery
•patients taking GLP-1 receptor agonist (subcutaneous for weight management and/or blood glucose control in type II diabetes mellitus, N = 45)
•patients not taking GLP-1 receptor agonist (N =45)

Exclusion criteria

•confounding delayed gastric emptying due to pregnancy
•previous esophageal or gastric operation
•etiologies at increased risk for delayed gastric emptying (hiatal hernia, Parkinson's disease, scleroderma, multiple sclerosis, and amyloidosis)
•on medication that could potentially cause gastroparesis or delayed gastric or intestinal emptying (opioids, proton pump inhibitors, tricyclic antidepressants, calcium channel blockers, antipsychotic medications, loperamide, diphenoxylate, oxybutynin, hyoscine butylbromide, scopolamine, promethazine, glycopyrrolate, atropine, chlordiazepoxide, and lithium)

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other clinical outcomes
2
Safety / tolerability / PK
1
Other (unclassified)
1

Safety / tolerability / PK

1 endpoint
Secondary/protocol endpoint

Number of occurrences requiring change in anesthetic management plan

Time frame:From time of preoperative ultrasound in holding area to anesthesia induction in operating room

event count, event

Other clinical outcomes

2 endpoints
Primary/protocol endpoint

Number of participants presenting with a full stomach

Time frame:Measured in the preoperative holding area

event count, event

Secondary/protocol endpoint/low confidence

Relationship between dose, duration and timing of GLP-1 receptor agonist and gastric volume

Time frame:Measured in the preoperative holding area

descriptive

Other (unclassified)

1 endpoint
Secondary/protocol endpoint/low confidence

Relationship between gastric emptying and purpose of GLP-1 receptor agonist administration

Time frame:Measured in the preoperative holding area

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.